Abstract:Cardiovascular diseases are the leading cause of mortality worldwide and about 25% of cardiovascular deaths are due to disturbances in cardiac rhythm or "arrhythmias". Arrhythmias were traditionally treated with antiarrhythmic drugs, but increasing awareness of the risks of presently available antiarrhythmic agents has greatly limited their usefulness. Most common treatment algorithms still involve small molecule drugs, and antiarrhythmic agents with improved efficacy and safety are sorely needed. This paper reviews the model systems that are available for discovery and development of new antiarrhythmic drugs. We begin with a presentation of screening methods used to identify specific channel-interacting agents, with a particular emphasis on high-throughput screens. Traditional manual electrophysiological methods, automated electrophysiology, fluorescent dye methods, flux assays and radioligand binding assays are reviewed. We then discuss a variety of relevant arrhythmia models. Two models are widely used in testing for arrhythmogenic actions related to excess action potential prolongation, an important potential adverse effect of chemical entities affecting cardiac rhythm: the methoxamine-sensitized rabbit and the dog with chronic atrioventricular block. We then go on to review models used to assess potential antiarrhythmic actions. For ventricular arrhythmias, chemical induction methods, cardiac or neural electrical stimulation, ischaemic heart models and models of cardiac channelopathies can be used to identify effective antiarrhythmic agents. For atrial arrhythmias, potentially useful models include vagally-maintained atrial fibrillation, acute asphyxia with atrial burst-pacing, sterile pericarditis, Y-shaped atria surgical incisions, chronic atrial dilation models, atrial electrical remodelling due to sustained atrial tachycardia, heart failure-related atrial remodelling, and acute atrial ischaemia. It is hoped that the new technologies now available and the recently-developed models for arrhythmia-response assessment will permit the introduction of newer and more effective antiarrhythmic therapies in the near future.

Animal models of arrhythmia: classic electrophysiology to genetically modified large animals

The ECG in cardiovascular-relevant animal models of electrophysiology

Large Mammalian Animal Models of Heart Disease

Small Mammalian Animal Models of Heart Disease.

Animal models for atrial fibrillation: clinical insights and scientific opportunities

Model systems for the discovery and development of antiarrhythmic drugs

Anti‐arrhythmic investigations in large animal models of atrial fibrillation

Therapeutic advances in atrial fibrillation based on animal models

In Vivo Approaches to Understand Arrhythmogenic Cardiomyopathy: Perspectives on Animal Models

Use of animal models of atrial fibrillation in the study of cellular and molecular therapy

Research('s) Sweet Hearts: Experimental Biomedical Models of Diabetic Cardiomyopathy

Animal models for cardiac arrhythmias.

In Vivo Cardiac Electrophysiology in Mice: Determination of Atrial and Ventricular Arrhythmic Substrates

New drug discovery of cardiac anti-arrhythmic drugs: insights in animal models

Intracardiac electrophysiology to characterize susceptibility to ventricular arrhythmias in murine models

Small and large animal models in cardiac contraction research: advantages and disadvantages

Multicellular In vitro Models of Cardiac Arrhythmias: Focus on Atrial Fibrillation

Animal Models for Cardiovascular Research

Ventricular Arrhythmias in First Acute Myocardial Infarction: Epidemiology, Mechanisms, and Interventions in Large Animal Models

Computational modeling of cardiac electrophysiology and arrhythmogenesis: toward clinical translation

Animal Models of Ischemic Heart Disease for in Vivo Cardiac MR Imaging Research